Digital Health company to leverage its physiology-based predictive analytics engine, Biovitals™, to provide acute care at home
Biofourmis, a fast-growing digital health startup that augments personalized care using digital therapeutics, has entered into a collaboration with Brigham and Women’s Hospital to co-develop improvements to their proprietary analytics engine, Biovitals™ for Brigham’s Home Hospital Program.
In Brigham’s Home Hospital program, patients are cared for in their home instead of the hospital, aiming to provide the right care to the right patient at the right time in the right place. Doctors, nurses, and other clinical care team members visit the patient’s home. Their work is supplemented with state-of-the-art monitoring technology and most of the care a patient would expect in the hospital. Brigham has cared for over 200 patients at home for about two years. Preliminary pilot data in a randomized clinical trial have found similar quality, safety, and experience outcomes as those in the hospital at about half the cost1.
“Our home hospital team is hoping to improve care for our patients by creating a suite of highly clinically-useful algorithms that can predict deterioration and improvement for those who are acutely ill,” said David Levine MD, MPH, MA
To further improve patient care, this collaboration will harness and clinically utilize the vast quantity of biometric data that the home hospital team collects. They plan to use the Biovitals™ analytics engine and further innovate around new predictive algorithms. Unlike traditional threshold-based physiology monitoring, Biovitals™ uses advanced machine learning to learn a patient’s physiology and then dynamically build a personalized physiology signature that can detect subtle physiological changes that may predict a patient’s health. The program would also use Biofourmis’ RhythmAnalytics™ platform to detect dozens of different cardiac arrhythmia.
“Current remote monitoring systems are based on univariate physiology analysis and have shown high false alarm burden and no early intervention, especially while monitoring patients in an ambulatory setting. This collaboration would enable us to enhance and co-develop new predictive models for monitoring acutely ill patients suffering from multiple conditions like heart failure, pneumonia, COPD, and atrial fibrillation at-home, enabling clinicians to intervene early and improve the level of safety of patients,” said Kuldeep Singh Rajput, Founder & CEO of Biofourmis.
“Our home hospital team is hoping to improve care for our patients by creating a suite of highly clinically-useful algorithms that can predict deterioration and improvement for those who are acutely ill,” said David Levine MD, MPH, MA, researcher and lead for Brigham and Women’s Home Hospital program.
Biofourmis is on a mission of augmenting personalized care with Digital Therapeutics. Founded in Singapore, they discover, develop and deliver clinically-validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized AI-empowered health analytics platform that predicts clinical exacerbation days in advance before a critical event, which is the backbone of their Digital Therapeutics. They have a pipeline of products and product candidates across therapeutic areas, including heart failure, acute coronary syndrome, COPD, and chronic pain. Their lead product, BiovitalsHFTM, is the first digital therapeutics which utilizes software (along with wearable biosensor(s), adjunctive pharmacotherapy and live clinical support) to manage patients suffering from heart failure.
1 Levine D, Ouchi K, Blanchfield B, Diamond K, CT P, Schnipper J. Hospital-Level Care at Home for Acutely Ill Adults: A Pilot Randomized Controlled Trial. J GEN INTERN MED (2018) 33: 729. https://doi.org/10.1007/s11606-018-4307-z